TNX-1500, a crystallizable fragment–modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival
American Journal of Transplantation · 2023
DOI: 10.1016/j.ajt.2023.03.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Transplantation, 2023. Verfasst von Shuhei Miura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Cardiovascular …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Graft Rejection. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Blockade of the CD40/CD154 T cell costimulation pathway is a promising approach to supplement or replace current clinical immunosuppression in solid organ transplantation. We evaluated the tolerability and activity of a novel humanized anti-CD154 monoclonal antibody, TNX-1500 (TNX), in a nonhuman primate heterotopic cardiac allogeneic (allo) transplant model. TNX-1500 contains a rupluzimab fragment antigen-binding region and an immunoglobin G4 crystallizable fragment region engineered to reduce binding to the crystallizable fragment gamma receptor IIa and associated risks of thrombosis. Recipients were treated for 6 months with standard-dose TNX (sTNX) monotherapy, low-dose TNX monotherapy (loTNX), or loTNX with mycophenolate mofetil (MMF) (loTNX + MMF). Results were compared with historical data using chimeric humanized 5c8 monotherapy dosed as for loTNX but discontinued at 3 months. Median survival time was similar for humanized 5c8 and both loTNX groups, but significantly longer with sTNX (>265 days) than with loTNX (99 days) or loTNX + MMF (88 days) (P < 0.05 for both comparisons against sTNX). Standard-dose TNX prevented antidonor alloantibody elaboration, inhibited chronic rejection, and was associated with a significantly reduced effector T cells/regulatory T cells ratio relative to loTNX with MMF. No thrombotic complications were observed. This study demonstrated that TNX was well tolerated, prolongs allograft survival, and prevents alloantibody production and cardiac allograft vasculopathy in a stringent preclinical nonhuman primate heart allotransplant model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Cardiovascular Surgery, Sapporo Medical University, Sapporo, Japan; Department of Car…
- Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Anesthesiology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Tonix Pharmaceuticals, Chatham, New Jersey, USA.
- College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
Zitieren
APA
Miura, S., Habibabady, Z. A., Pollok, F., Ma, M., Rosales, I. A., Kinoshita, K., Pratts, S., McGrath, G., Chaban, R., Fogarty, S., Meibohm, B., Daugherty, B., Lederman, S., & Pierson, R. N. (2023). TNX-1500, a crystallizable fragment–modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival. American Journal of Transplantation. https://doi.org/10.1016/j.ajt.2023.03.025
Vancouver
Miura S, Habibabady ZA, Pollok F, Ma M, Rosales IA, Kinoshita K, et al. TNX-1500, a crystallizable fragment–modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival. American Journal of Transplantation. 2023. doi:10.1016/j.ajt.2023.03.025
BibTeX
@article{Miura2023,
author = {Miura, Shuhei and Habibabady, Zahra A and Pollok, Franziska and Ma, Madelyn and Rosales, Ivy A and Kinoshita, Kohei and Pratts, Shannon and McGrath, Gannon and Chaban, Ryan and Fogarty, Siobhan and Meibohm, Bernd and Daugherty, Bruce and Lederman, Seth and Pierson, Richard N},
title = {TNX-1500, a crystallizable fragment–modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival},
journal = {American Journal of Transplantation},
year = {2023},
doi = {10.1016/j.ajt.2023.03.025}
}
EUVIMED